Physician profile
Michael B Tom
NPI 1770522807
$6,785.91
in general payments reported to CMS, 2019-2025
37 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 83% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $403 · 2021: $1,045 · 2022: $1,174 · 2023: $1,542 · 2024: $866 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,554.88 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,079.48 | 2019-2025 | |
| Genzyme Corporation | $1,024.23 | 2019-2025 | |
| Optinose US, INC. | $522.30 | 2019-2025 | |
| Pfizer INC. | $430.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $382.52 | 2019-2025 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $277.33 | 2022-2025 | Hyqvia, Cuvitru |
| Hikma Pharmaceuticals USA | $205.89 | 2022-2024 | Ryaltris |
| Alk-Abello, INC | $140.48 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Regeneron Healthcare Solutions, INC. | $129.87 | 2020-2025 | Dupixent |
| Stryker Corporation | $121.23 | 2019-2025 | Scopis Ent |
| Inspire Medical Systems, INC. | $89.87 | 2023-2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Amgen INC. | $52.47 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.33 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $49.50 | 2023 | Ayvakit |
| Incyte Corporation | $47.54 | 2021-2022 | |
| Csl Behring | $46.11 | 2021 | |
| Aerin Medical INC. | $45.56 | 2025 | |
| Leo Pharma INC. | $43.65 | 2025 | Anzupgo |
| Phadia US INC. | $39.99 | 2023-2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $39.57 | 2022 | |
| Kaleo, INC. | $37.68 | 2023 | Auvi-Q |
| Lilly USA, LLC | $28.24 | 2025 | Ebglyss, Taltz |
| Integra Lifesciences Corporation | $27.21 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Genentech USA, INC. | $26.54 | 2025 | Xolair |
| Aimmune Therapeutics, INC. | $25.00 | 2022 | |
| Medtronic, INC. | $23.27 | 2023 | Propel |
| Pharming Healthcare, INC. | $23.19 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $21.00 | 2020 | |
| Merck Sharp & Dohme LLC | $20.70 | 2023 | |
| Grifols USA, LLC | $20.11 | 2025 | Gamunex-C |
| Abbvie INC. | $18.46 | 2025 | |
| Medtronic USA, INC. | $17.55 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.50 | 2021 | |
| Bio Products Laboratory USA, INC. | $14.37 | 2022 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.